Olema Pharmaceuticals, Inc.
Formerly CombiThera, Inc.
Olema Pharmaceuticals, Inc. is listed today as Olema Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2024 | $250 M | Private placement after listing | $250 million to $1 billion | equity, options | SEC | |
| Sep 2023 | $130 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Sep 2020 | $87 M | No. 3 | $50 to $250 million | equity | SEC | |
| Mar 2020 | $54 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2018 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Olema Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2024).
SEC Form D · Dec 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2024
That is all the official record says: Olema Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Olema Pharmaceuticals, Inc. are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock (Form 3, 2020) | SEC Form 3 |
| Biotechnology Value Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Biotechnology Value Trading Fund OS LP | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock (Form 3, 2020) | SEC Form 3 |
| BVF GP Holdings LLC | Other | not stated | not stated | Held Series A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BVF I GP LLC | Other | not stated | not stated | Held Series A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BVF II GP LLC | Other | not stated | not stated | Held Series A-1, B and C preferred stock (Form 3, 2020) | SEC Form 3 |
| BVF Inc/il | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| BVF Partners L P/il | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| BVF Partners OS Ltd. | Fund or asset manager | not stated | not stated | Held Series A-1, B and C preferred stock (Form 3, 2020) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cyrus Harmon | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Frank McCormick | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Peter J. Kushner | Person | not stated | not stated | Held Series A and A-1 preferred stock (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 27 investors.
Largest shareholders today
Institutions holding Olema Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- FMR LLC$99 M13.07%
- Paradigm Biocapital Advisors LP$75 M9.95%
- BlackRock, Inc.$62 M8.20%
- Bain Capital Life Sciences Investors, LLC$61 M8.09%
- Janus Henderson Group Ltd.$55 M7.21%
- BVF Inc/il$46 M6.05%
- Siren, L.L.C.$42 M5.54%
- State Street Corp$33 M4.39%
- Vanguard Capital Management LLC$30 M4.01%
- Logos Global Management LP$28 M3.66%
- Morgan Stanley$21 M2.72%
- Franklin Templeton Inc$20 M2.59%
- Deep Track Capital, LP$18 M2.41%
- Geode Capital Management, LLC$17 M2.25%
- Cormorant Asset Management, LP$15 M2.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David C. Myles, Ph.D. | Executive officer | Dec 2024 |
| Naseem C. Zojwalla, M.D. | Executive officer | Dec 2024 |
| Sean Bohen, M.D., Ph.D. | Executive officer | Dec 2024 |
| Shane C. Kovacs | Executive officer | Dec 2024 |
| Cyrus Harmon | Executive officer | Oct 2020 |
| David Myles | Executive officer | Oct 2020 |
| John Moriarty | Executive officer | Oct 2020 |
| Kinney Horn | Executive officer | Oct 2020 |
| Peter Kushner | Executive officer | Oct 2020 |
| Sean Bohen | Executive officer | Oct 2020 |
| Shane Kovacs | Executive officer | Oct 2020 |
| Pamela Klein | Executive officer | Jun 2020 |
| Frank McCormick | Executive officer | Mar 2020 |
| Peter Kusher | Executive officer | Aug 2018 |
| Andrew C. Rappaport | Director | Dec 2024 |
| Cynthia C. Butitta | Director | Dec 2024 |
| Cyrus L. Harmon, Ph.D. | Director | Dec 2024 |
| Gorjan L. Hrustanovic, Ph.D. | Director | Dec 2024 |
| Graham L. Walmsley, M.D., Ph.D. | Director | Dec 2024 |
| Ian L. Clark | Director | Dec 2024 |
| Sandra L. Horning, M.D. | Director | Dec 2024 |
| Scott L. Garland | Director | Dec 2024 |
| Sean Bohen, M.D., Ph.D. | Director | Dec 2024 |
| Yi C. Larson | Director | Dec 2024 |
| Andrew Rappaport | Director | Oct 2020 |
| Cynthia Butitta | Director | Oct 2020 |
| Cyrus Harmon | Director | Oct 2020 |
| Frank McCormick | Director | Oct 2020 |
| Gorjan Hrustanovic | Director | Oct 2020 |
| Graham Walmsley | Director | Oct 2020 |
| Ian Clark | Director | Oct 2020 |
| Sean Bohen | Director | Oct 2020 |
| Gorjan Hrustanovich | Director | Mar 2020 |
| Andrei Manoliu | Director | Aug 2018 |
| Lawrence Fritz | Director | Aug 2018 |
| Marina Bozilenko | Director | Aug 2018 |
| Peter Kusher | Director | Aug 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.